# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

			01			Sompariy Not of 1540					
1. Name and Address of Reporting Person* <u>VIVO VENTURES VII, LLC</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol MEI Pharma, Inc. [MEIP]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				<u></u>		1		Director	Х	10%	Owner
(Last) 575 HIGH STR SUITE 201	(First) EET	(Middle)		Date of Earliest Trar /28/2013	nsaction (Mon	th/Day/Year)	Officer (give title below)			Other (specify pelow)	
			4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) PALO ALTO	CA	94301					X	Form filed by Or Form filed by Mo Person		0	
(City)	(State)	(Zip)									
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
Date			2. Transaction Date	2A. Deemed Execution Date,	3. Transaction	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a		5. Amount of Securities	6. Owner Form: Di	rect	7. Nature of Indirect

#### lonth/Day/Year) Beneficial Ownership (Instr. 4) (Month/Day/Year) 8) (D) or indire (I) (Instr. 4) Owned Following Reported Transaction(s) (Instr. 3 and 4) (A) or (D) Code v Amount Price See 06/28/2013 \$7.5777(1) Common Stock S 7,337 3,979,758 I D footnote<sup>(2)</sup>

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			( 371	,	,		,	• *			,				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (	Transaction of Code (Instr. Derivative		erivative (Month/Day/Year) ecurities cquired A) or isposed f (D) nstr. 3, 4		7. Title Amoun Securi Under Deriva Securi and 4)	nt of ties ying tive ty (Instr. 3	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

1. Name and Address of Reporting Person\*

VIVO	<u>VENTURES</u>	<u>VII, LLC</u>

(Last)	(First)	(Middle)						
575 HIGH STREET								
SUITE 201								
(Street)								
PALO ALTO	CA	94301						
(City)	(State)	(Zip)						
1. Name and Address o	f Reporting Person <sup>*</sup>							
Vivo Ventures F								
(Last)	(First)	(Middle)						
575 HIGH STREET								
SUITE 201								
P								
(Street)								
PALO ALTO	CA	94301						
(City)	(State)	(Zip)						
	*							
	1. Name and Address of Reporting Person*							
<u>Vivo Ventures VII Affiliates Fund, L.P.</u>								
(Last)	(First)	(Middle)						

575 HIGH STREET						
SUITE 201						
(Street) PALO ALTO	СА	94301				
(City)	(State)	(Zip)				

## Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.48 to \$7.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. 2. Includes 3,894,871 shares held of record by Vivo Ventures Fund VII, L.P., and 84,887 shares held of record by Vivo Ventures VII Affiliates Fund, L.P. (together, the "Vivo VII Funds"). Vivo Ventures VII, LLC (the "Vivo VII GP"), as the sole general partner of both of the Vivo VII Funds, may be deemed to beneficially own the Common Stock of the Issuer owned by the Vivo VII Funds. Vivo VII GP disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.

### **Remarks:**

<u>/s/ Albert Cha, Managing</u> <u>Member of Vivo Ventures VII,</u> <u>LLC</u>	<u>07/02/2013</u>
<u>/s/ Albert Cha, Managing</u> <u>Member of Vivo Ventures</u> <u>Fund VII, L.P. and Vivo</u> <u>Ventures VII, LLC, its General</u> <u>Partner</u>	<u>07/02/2013</u>
<u>/s/ Albert Cha, Managing</u> <u>Member of Vivo Ventures VII</u> <u>Affiliates Fund, L.P. and Vivo</u> <u>Ventures VII, LLC, its General</u> <u>Partner</u>	<u>07/02/2013</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.